Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gastrointestinal tumours, colorectal 2

2341 - MiR-31-3p is a predictive biomarker of cetuximab response in FIRE3 clinical trial


10 Oct 2016


Gastrointestinal tumours, colorectal 2


Pierre Laurent-Puig


Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370


P. Laurent-Puig1, M. Grisoni2, V. Heinemann3, K. Fontaine2, C. Vazart2, V. Decaulne2, F. Rousseau2, B. Courtieu2, F. Lieabert2, A. Jung4, D. Neureiter5, R. Thiébaut2, S. Stintzing6

Author affiliations

  • 1 Université Paris Descartes, Sorbonne Paris Cité, France; Department Of Biology, Hôpital Européen Georges Pompidou, Paris, France; Inserm Umr-s1147, Assistance Publique - Hopitaux De Paris, 75006 - Paris/FR
  • 2 R&d, Integragen, 91000 - Evry/FR
  • 3 Medical Dept. Iii, Klinikum der Universität München, München/DE
  • 4 Institute Of Pathology, Klinikum der Universität München, München/DE
  • 5 Pathology, Paracelsus University Hospital Salzburg, Salzburg/AT
  • 6 Hematology And Oncology, Ludwig Maximilians University - Grosshadern, 81377 - München/DE


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2341


MiR-31-3p expression has been shown to be predictive of cetuximab efficacy on survival in RAS wild-type (WT) mCRC patients receiving anti-EGFR theray in the FIRE-3 clinical trial. Patients were defined as low or high miR-31-3p expressors based on a cutoff threshold defined in a previous study. When treated with cetuximab, patients with low miR-31-3p expression have a better survival than patients with high expression. We aimed to investigate the miR-31-3p predictivity on clinical endpoints for response.


MiR-31-3p expression was measured by qRTPCR after extraction from 370 RAS WT paraffin embedded tumor samples. 191 patients were treated with FOLFIRI plus bevacizumab and 179 FOLFIRI plus cetuximab in first line therapy. Objective response and disease control were analyzed in clinical centers based on RECIST criteria. An independent centralized radiological review reassessed patients for early tumor shrinkage (ETS) and Depth of response (DoR). ETS was defined as a diminution of 20% of the diameter at the first CT scan at 6 weeks after baseline. Response rates by treatment arms were compared through odds ratios estimated using logistic regression multivariate models. MiR-31-3p predictivity on response was assessed by testing interaction of treatment effect with miR-31-3p expression in low or high expressors groups (α = 0.10). When heterogeneity of treatment effect was detected, analyses were performed separately in both groups.


A benefit of cetuximab therapy on objective response was seen only in low miR-31-3p expressors patients (OR = 3.37 [1.70–6.67], p = 0.0005 versus OR = 1.25 [0.56–2.77], p = 0.6 in high expressors). In low expressors, objective response rate was 70% in patients treated with cetuximab and 57% in patients treated with bevacizumab. Disease control rate were similar in the cetuximab arm and bevacizumab arms (80% and 86% respectively), and homogeneous across miR-31-3p expression groups. MiR-31-3p expression is predictive of the DoR and ETS (interaction test: p = 0.0001 and p = 0.02 respectively).


Benefit of cetuximab on response is restricted to patients with low miR-31-3p expression. MiR-31-3p could be clinically useful to select patients for first line anti-EGFR therapy.

Clinical trial identification

Legal entity responsible for the study





P. Laurent-Puig: Honoraria from: Merck-Serono, Roche, Sanofi, Boerhinger Ingelheim Consulting: Merck-Serono, Boerhinger Ingelheim Intellectual property: Integragen. M-L. Grisoni, K. Fontaine, V. Decaulne, F. Rousseau, B. Courtieu, F. Lieabert, R. Thiébaut: Integragen employee. V. Heinemann: Honoraria: Merck, Amgen, Roche, Sanofi, Baxalta, Sirtex Board: Merck, Amgen, Roche, Sanofi, Baxalta, Sirtex Research funding (my institution): Merck, Amgen, Roche, Sanofi Travel accommodation expenses: Merck, Roche, Sirtex, Baxalta. C. Vazart: IntegraGen employee. A. Jung: Honoraria as a speaker: Amgen, AstraZeneca, Merck KgaA, Qiagen, Roche Advisory Boards: Amgen, AstraZeneca, Biocartis, Cellgen, GSK, Merck KgaA, Novartis, Pfizer, Roche. S. Stintzing: Honoraria for Talks: Amgen, Roche, Merck KgaA, Bayer, Sanofi Advisory Boards: Amgen, Roche, Merck KgaA, Bayer, Sanofi. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings